Cue Biopharma, Inc. (NASDAQ:CUE) Short Interest Update

Cue Biopharma, Inc. (NASDAQ:CUE) was the target of a significant growth in short interest during the month of September. As of September 30th, there was short interest totalling 3,800,000 shares, a growth of 6.7% from the September 15th total of 3,560,000 shares. Based on an average trading volume of 577,000 shares, the days-to-cover ratio is presently 6.6 days.

Cue Biopharma Stock Up 3.7 %

Shares of NASDAQ:CUE traded up $0.04 during trading on Thursday, reaching $1.11. 312,208 shares of the stock were exchanged, compared to its average volume of 409,055. Cue Biopharma has a 1-year low of $0.45 and a 1-year high of $3.25. The stock has a fifty day moving average of $0.75 and a two-hundred day moving average of $1.17. The company has a debt-to-equity ratio of 0.11, a current ratio of 2.06 and a quick ratio of 2.06. The firm has a market cap of $53.99 million, a price-to-earnings ratio of -1.03 and a beta of 1.96.

Cue Biopharma (NASDAQ:CUE) last released its quarterly earnings data on Wednesday, August 14th. The company reported ($0.20) earnings per share for the quarter, topping the consensus estimate of ($0.29) by $0.09. Cue Biopharma had a negative net margin of 566.02% and a negative return on equity of 142.93%. The firm had revenue of $2.66 million for the quarter, compared to the consensus estimate of $1.12 million. During the same quarter in the prior year, the company posted ($0.29) earnings per share. Research analysts anticipate that Cue Biopharma will post -0.85 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the stock. Wedmont Private Capital grew its position in Cue Biopharma by 100.0% in the 1st quarter. Wedmont Private Capital now owns 40,000 shares of the company’s stock worth $76,000 after purchasing an additional 20,000 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Cue Biopharma during the 2nd quarter worth approximately $66,000. Good Life Advisors LLC boosted its stake in shares of Cue Biopharma by 23.1% in the 3rd quarter. Good Life Advisors LLC now owns 400,000 shares of the company’s stock worth $303,000 after buying an additional 75,000 shares during the last quarter. Finally, Vanguard Group Inc. grew its holdings in shares of Cue Biopharma by 7.1% in the first quarter. Vanguard Group Inc. now owns 2,283,362 shares of the company’s stock valued at $4,316,000 after acquiring an additional 150,457 shares in the last quarter. Hedge funds and other institutional investors own 35.04% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have issued reports on CUE shares. Piper Sandler dropped their price target on Cue Biopharma from $8.00 to $3.00 and set an “overweight” rating on the stock in a research note on Friday, July 26th. Stifel Nicolaus cut their target price on shares of Cue Biopharma from $8.00 to $4.00 and set a “buy” rating on the stock in a research note on Tuesday, August 20th. Finally, JMP Securities reduced their price target on shares of Cue Biopharma from $15.00 to $2.00 and set a “market outperform” rating for the company in a report on Friday, July 26th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat, Cue Biopharma currently has a consensus rating of “Buy” and an average price target of $5.00.

About Cue Biopharma

Cue Biopharma, Inc, a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer.